舒肝宁注射液与替诺福韦联合治疗慢性乙型肝炎肝硬化的效果  

Effect of Shuganning injection combined with tenofovir in the treatment of chronic hepatitis B complicated by liver cirrhosis

作　　者：苏立 张金良 蔡峻岭 Su Li;Zhang Jinliang;Cai Junling(Department of Infective Diseases,Zhumadian Central Hospital,Zhumadian 463000,China)

机构地区：[1]驻马店市中心医院感染科,驻马店463000

出　　处：《中国实用医刊》2024年第20期103-106,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析舒肝宁注射液与替诺福韦联合治疗慢性乙型肝炎肝硬化的效果。方法队列研究。抽取2020年10月至2023年10月驻马店市中心医院收治的60例慢性乙型肝炎肝硬化患者,采用随机数字表法分为单一治疗组和联合治疗组,每组30例。单一治疗组给予替诺福韦,联合治疗组在单一治疗组基础上加用舒肝宁注射液。比较两组临床疗效、肝功能[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)]、脱氧核糖核酸(HBV-DNA)转阴率、乙型肝炎E抗原(HBeAg)转阴率、肝脏硬度值、肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)]、免疫功能[自然杀伤细胞(NK)及T淋巴细胞CD3^(+)、CD4^(+)]。结果两组总有效率比较差异未见统计学意义(P>0.05)。治疗后,联合治疗组ALT、AST、ALP、肝脏硬度值、LN、HA、PCⅢ低于单一治疗组,NK、CD3^(+)、CD4^(+)高于单一治疗组(P<0.05)。联合治疗组HBV-DNA、HBeAg转阴率(90.00%,27/30;60.00%,18/30)高于单一治疗组(66.67%,20/30;33.33%,10/30),P<0.05。结论舒肝宁注射液与替诺福韦联合治疗慢性乙型肝炎肝硬化患者,可抑制肝纤维化,增强免疫功能,改善肝功能。Objective To analyze the effect of Shuganning injection combined with tenofovir in the treatment of chronic hepatitis B complicated by liver cirrhosis.Methods Sixty patients with chronic hepatitis B complicated by liver cirrhosis admitted to Zhumadian Central Hospital from October 2020 to October 2023 were selected for the cohort study.And they were divided into single treatment group and combined treatment group using a random number table method,with 30 cases in each group.The single treatment group was treated with tenofovir,and the combined treatment group was treated with Shuganning injection based on the treatment of the single treatment group.The clinical efficacy,liver function assessed by alanine transaminase(ALT),aspartate transaminase(AST)and alkaline phosphatase(ALP),negative conversion rate of hepatitis B virus deoxyribonucleic acid(HBV-DNA),negative conversion rate of hepatitis Be antigen(HBeAg),liver stiffness value,liver fibrosis indexes including hyaluronic acid(HA),laminin(LN)and procollagen typeⅢ(PCⅢ),immune function assessed by natural killer cells(NK)and T lymphocytes including cluster of differentiation 3^(+)(CD3^(+))and cluster of differentiation 4^(+)(CD4^(+))were compared between the two groups.Results There was no significant difference in total effective rate between the two groups(P>0.05).After treatment,ALT,AST,ALP,liver stiffness value,LN,HA and PCⅢin the combined treatment group were lower than those in the single treatment group,while NK,CD3^(+)and CD4^(+)were higher than those in the single treatment group(P<0.05).The negative conversion rates of HBV-DNA and HBeAg in the combined treatment group(90.00%,27/30;60.00%,18/30)were higher than those in the single treatment group(66.67%,20/30;33.33%,10/30),P<0.05.Conclusions Shuganning injection combined with tenofovir in the treatment of chronic hepatitis B patients with liver cirrhosis can inhibit progress of liver fibrosis,enhance immune function,and improve liver function.

关 键 词：慢性乙型肝炎 肝硬化 舒肝宁注射液 替诺福韦 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]